Background Recent data indicate a higher level of effectivity of β‐lactam antibiotics if serum
concentrations are kept above the minimal inhibitory concentration (MIC) of the pathogen …

Obesity is a significant global health problem and has been associated with altered
pharmacokinetics and pharmacodynamics of many drugs. However, little is known regarding …

Purpose Standard dosing and intermittent bolus application (IB) are important risk factors for
pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in …

Piperacillin-tazobactam is a potent β-lactam/β-lactamase inhibitor antibiotic commonly
prescribed in the intensive care unit setting. Admitted patients often show large variability in …

Background Several studies have indicated that commonly used piperacillin-tazobactam
(TZP) and meropenem (MEM) dosing regimens lead to suboptimal plasma concentrations …

The treatment of infections is mainly based on experience rather than on rational design.
Although some attempts have been made to correlate pharmacokinetic and …

Piperacillin/tazobactam (TZP) is administered intravenously in a fixed ratio (8: 1) with the
potential for inadequate tazobactam exposure to ensure piperacillin activity against …

Background It is important to optimize dosing schemes of antibiotics to maximize the
probability of therapeutic success. The recommended pharmacokinetic/pharmacodynamic …

Background and Objectives A quantitative evaluation of the PK of meropenem, a broad-
spectrum β-lactam antibiotic, in plasma and interstitial space fluid (ISF) of subcutaneous …

OBJECTIVE: To mathematically assess drug losses due to infusion line residuals and
evaluate methods to compensate for drug loss due to residual volumes in intravenous pump …